OakChart

Phibro Animal Health Corp

PAHCHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 11:16 AM ET

34.82+0.18 (0.53%)
2026-11-11 17:16 CET
Market cap
1,406.44 USD m
Revenue, TTM
1,540.97 USD m
Net income, TTM
102.71 USD m
Free cash flow, TTM
21.67 USD m
EPS diluted, TTM
2.51
P/E
13.90
Compare

Price

PAHC against its 20, 50 and 200-day averages
2050200miss
30.0040.0050.00496K991KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PAHCclose 34.8220-day 37.7050-day 36.88200-day 41.0834.8252w low

42.0% under the 52-week high of 60.08 on 13 Apr 2026. 52-week low 28.25 on 2 Jun 2026. Last 15 sessions, 24.2% high to low

Profile

PAHC
52-week range, 21% of the way up
28.2560.08

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment focuses on the development and marketing of medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment is involved in the manufacture and marketing of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

IndexRUT
Employees2605
IPOApr 11, 2014
Beta0.42
ATR, 14d1.69
Rel volume0.20
Short float4.87%
Insider own48.48%
Inst own51.78%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.41B
Enterprise Value2.12B
Income102.71M
Sales1.54B
Book/sh10.29
Cash/sh2.05
Dividend Est.0.48 (1.38%)
Dividend TTM0.48 (1.38%)
Dividend Ex-DateNov 25, 2026
Dividend Gr. 3/5Y0.00% 0.00%
Payout19.72%
Employees2605
IPOApr 11, 2014

Ratios

P/E13.90
Forward P/E9.02
PEG1.03
P/S0.92
P/B3.39
P/C17.01
P/FCF65.25
EV/EBITDA8.30
EV/Sales1.38
Quick Ratio1.28
Current Ratio3.20
Debt/Eq1.89
LT Debt/Eq1.81
Option/ShortYes / Yes

Earnings

EPS (ttm)2.51
EPS next Y3.86
EPS next Q0.94
EPS this Y8.28%
EPS next Y10.71%
EPS next 5Y8.78%
EPS past 3/5Y44.61% 12.64%
Sales past 3/5Y15.79% 12.74%
EPS Y/Y TTM51.28%
Sales Y/Y TTM10.10%
EPS Q/Q11.06%
Sales Q/Q6.29%
EarningsNov 04 AMC
EPS/Sales Surpr.0.93% 1.15%

Ownership

Insider Own48.48%
Insider Trans0.05%
Inst Own51.78%
Inst Trans0.01%
ROA7.08%
ROE28.17%
ROIC8.76%
Gross Margin33.65%
Oper. Margin13.18%
Profit Margin6.67%
SMA20-7.64%
SMA50-5.58%
SMA200-15.24%
Trades-

Technical

Shs Outstand21.11M
Shs Float20.92M
Short Float4.87%
Short Ratio4.47
Short Interest1.02M
52W High60.08 -42.04%
52W Low28.25 23.27%
Volatility6.88% 4.44%
ATR (14)1.69
RSI (14)41.41
Beta0.42
Rel Volume0.20
Avg Volume228.02K
Volume13,714

Performance

Perf Week-11.68%
Perf Month-5.40%
Perf Quarter2.24%
Perf Half Y-1.24%
Perf YTD-6.79%
Perf Year-23.18%
Perf 3Y260.50%
Perf 5Y53.07%
Perf 10Y21.34%
Recom2.33
Target Price47.00
Prev Close34.64
Price34.82
Change %0.53%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Apr 15, 2026InitiatedCCitigroupNeutral$62+78.0%
Jul 07, 2025UpgradeJJP MorganNeutral → Overweight$35+0.5%
Jun 16, 2025UpgradeBBNP Paribas ExaneUnderperform → Neutral$24-31.1%
Sep 10, 2024InitiatedJJP MorganNeutral$22-36.8%
Dec 07, 2023InitiatedEExane BNP ParibasUnderperform$9-74.2%
Dec 21, 2022InitiatedRROTH CapitalBuy$18-48.3%
Jul 25, 2022DowngradeBBarclaysEqual Weight → Underweight$22-36.8%
Jan 10, 2022UpgradeBBarclaysUnderweight → Equal Weight$23-34.0%
Nov 18, 2021InitiatedMMorgan StanleyEqual-Weight$23-34.0%
Aug 05, 2021ResumedCCredit SuisseNeutral$25-28.2%

Peers

Mkt cap
TickerCompanyMkt cap
ELANElanco Animal Health Inc13.18B
ZTSZoetis Inc32.93B
NEOGNeogen Corp2.57B
BCPCBalchem Corp5.47B
MRKMerck & Co Inc360.09B
ODCOil-Dri Corp Of America982.30M
IDXXIdexx Laboratories Inc54.93B
DARDarling Ingredients Inc8.42B
ADMArcher Daniels Midland Co33.24B
BGBunge Global SA19.12B

Insider trading

latest 14 of 69
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BFI Co. LLC10% OwnerSep 16 '26Proposed Sale35.30350,00012,355,000Sep 16 05:18 PM
Bendheim Daniel MOfficerAug 04 '26Proposed Sale36.6048617,787Aug 04 03:52 PM
Escudero Lisa AnnOfficerAug 04 '26Proposed Sale36.602659,699Aug 04 03:34 PM
David GlennOfficerAug 04 '26Proposed Sale36.6084030,744Aug 04 03:32 PM
BENDHEIM JACKOfficerAug 04 '26Proposed Sale36.602,30384,288Aug 04 03:31 PM
Miller Larry LeeOfficerAug 04 '26Proposed Sale36.6063523,241Aug 04 03:27 PM
Weinstein JudithOfficerAug 04 '26Proposed Sale36.6047217,275Aug 04 03:22 PM
BFI Co. LLC10% OwnerJun 16 '26Proposed Sale31.87281,6008,974,592Jun 16 06:04 PM
CORCORAN E THOMASDirectorMay 29 '26Buy31.7710,000317,70041,459Jun 02 06:56 PM
BENDHEIM JACKPresident and CEOMay 06 '26Sale57.377,040403,85060,680May 07 07:34 PM
BENDHEIM JACKPresident and CEOMay 05 '26Sale55.807,040392,81067,720May 07 07:34 PM
BENDHEIM JACKPresident and CEOMay 07 '26Sale48.494,528219,56856,152May 07 07:34 PM
BENDHEIM JACKPresident and CEOApr 28 '26Sale55.917,040393,57588,840Apr 30 07:20 PM
BENDHEIM JACKPresident and CEOApr 29 '26Sale52.927,040372,55381,800Apr 30 07:20 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
DFASU.S. Small Cap Portfolio-ETF Class Shares-
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • Phibro Matches EPS On A Revenue Beat, But Core Animal Health Slows To 3% And Guidance Stays Put (Earnings Whispers) -10.22%
  • Phibro: Fiscal Q1 Earnings Snapshot (Associated Press)
  • Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance (Business Wire)
  • Phibro Animal Health Corporation Declares Quarterly Dividend (Business Wire)
  • Phibro's Street Estimates Sit Above Its Own Outlook As Brazil Decision Looms (Earnings Whispers)
  • Loading…
  • Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results (Business Wire)
  • Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference (Business Wire)
  • Phibro Animal Health Corp (PAHC) (Q4 2026) Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
  • Phibro: Fiscal Q4 Earnings Snapshot (Associated Press)
  • Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance (Business Wire)
  • Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results (Business Wire)
  • Phibro Animal Health Corporation Declares Quarterly Dividend (Business Wire)
  • Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2027Q12026-11-040.7900.7830.720386.8382.423
2026Q42026-08-260.8500.7130.530396.7381.185
2026Q32026-05-060.7600.7130.585383.5367.025
2026Q22026-02-040.8700.6700.670373.9355.644
2026Q12025-11-050.7300.6230.649363.9347.014
2025Q42025-08-270.5700.5210.423378.7362.383
2025Q32025-05-070.6300.5210.513347.8352.193
2025Q22025-02-050.5400.4250.078309.3292.264
2025Q12024-11-060.3500.2480.172260.4246.74
2024Q42024-08-280.4100.3330.019273.2260.493
2024Q32024-05-080.3100.2900.207263.2253.653
2024Q22024-02-070.3300.2800.031249.9240.934
2024Q12023-11-080.1400.230-0.198231.32423
2023Q42023-08-300.3800.3730.284255256.134
2023Q32023-05-030.2900.3350.248245.7246.694
2023Q22023-02-080.3400.3030.178244.6241.294

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.5301.5371.350828829.87
2020FY1.0801.1280.828800.4805.59
2021FY1.2701.2631.343833.4827.38
2022FY1.3101.3381.214942.3938.41
2023FY1.2101.2200.805977.9979.13
2024FY1.1901.1200.0601,0181,003
2025FY2.0902.0331.1871,2961,278
2026FY3.2203.0742.4601,5181,498
2027FY-3.487--1,580
2028FY-3.860--1,634
2029FY-4.145--1,677
2030FY-4.810--1,732

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q2S2026-11-06110402402402
2027Q2S2026-11-05100392.67392.67392.67
2027Q2S2026-11-04100392.67392.67392.67
2027Q2S2026-10-16100392.67392.67392.67
2027Q2S2026-10-15200392.01391.35392.67
2027Q2S2026-09-25100391.35391.35391.35
2027Q2S2026-08-27200392.57391.35393.78
2027Q2R2026-11-061000.910.910.91
2027Q2R2026-08-271000.850.850.85
2027Q2E2026-11-102000.940.910.97
2027Q2E2026-11-062100.940.910.97
2027Q2E2026-11-052100.940.910.97
2027Q2E2026-11-042100.940.910.97
2027Q2E2026-10-162100.940.910.97

Estimate history

EPS, annual1.6071.350.8281.3431.2140.8050.061.1872.4342.5061
Period201820192020202120222023202420252026TTM
EPS, quarterly0.1720.0780.5130.4230.6490.670.5850.530.721
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Sales, annual819.982827.995800.354833.35942.261977.8891017.6791296.2151518.0931540.97
Period201820192020202120222023202420252026TTM
Sales, quarterly260.432309.261347.825378.697363.893373.91383.543396.747386.774
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Shares, annual40.35840.45440.45440.50440.50440.50440.50440.53440.56540.602
Period201820192020202120222023202420252026MRQ
Shares, quarterly40.50440.50440.53440.53440.53440.53440.56540.56540.602
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue1,540.971,518.091,296.211,017.68977.89942.26833.35800.35828.00
Cost of Goods Sold Incl. D&A1,022.371,007.91905.25705.19678.41655.42560.88543.08564.44
Gross Profit518.61510.18390.97312.49299.47286.84272.47257.28263.56
Selling, General and Administrative Excl. Other315.49309.33269.68250.07219.50207.34196.51183.98176.41
Research and Development-24.5523.7329.1924.3920.8317.7613.7412.08
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income203.12200.85121.2962.4279.9879.5075.9673.3087.14
Interest Expense36.911.992.6237.5128.559.7910.4014.3013.68
Unusual Expense19.5650.8845.42-5.40-1.744.624.414.413.92
Net Income Before Taxes139.86137.3567.9910.9254.0772.3366.4755.5171.50
Income Taxes37.1437.6319.738.5021.4623.1512.0821.9616.79
Consolidated Net Income102.7199.7248.262.4232.6149.1754.3833.5554.71
Net Income From Continuing Operations102.7199.7248.262.4232.6149.1754.3833.5554.71
Net Income102.7199.7248.262.4232.6149.1754.3833.5554.71
EPS (Recurring)2.843.301.97-0.030.771.291.420.901.42
EPS (Basic, Before Extraordinaries)2.532.461.190.060.811.211.340.831.35
EPS (Diluted)2.512.431.190.060.811.211.340.831.35
EBITDA255.38252.37166.8998.60113.99112.21107.85105.64114.71
Non-Operating Income (Expense)-6.79-10.63-5.25-19.390.907.245.320.931.96
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.631.260.570.380.000.000.821.651.65
Price To Earnings Ratio13.8213.8232.6851.6217.0215.7621.5231.7518.93
Price To Sales Ratio0.950.850.800.670.570.821.401.331.55
Gross Margin33.6533.6130.1630.7130.6230.4432.7032.1531.83
Operating Margin13.1813.239.366.138.188.449.129.1610.52
Net Margin6.676.573.720.243.335.226.534.196.61
Shares Outstanding40.6040.5640.5340.5040.5040.5040.5040.4540.45
Market Capitalization1,406.441,406.441,035.23679.25554.90774.831,169.741,062.721,285.22

Income statement, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q42025Q32025Q2
Total Revenue386.77396.75383.54373.91363.89378.70347.82309.26
Cost of Goods Sold Incl. D&A259.00263.11258.67241.59244.55270.82241.94210.53
Gross Profit127.78133.64124.87132.32119.35107.88105.8998.73
Selling, General and Administrative Excl. Other77.6283.0776.9077.9171.4574.3867.4066.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income50.1650.5747.9854.4147.8933.5038.4932.23
Interest Expense12.440.5310.8813.0613.480.4213.1013.57
Unusual Expense0.3312.603.123.51-4.318.391.532.91
Net Income Before Taxes38.7832.3432.3136.4236.2723.8529.694.84
Income Taxes9.2610.638.298.979.746.628.811.65
Consolidated Net Income29.5221.7124.0227.4626.5317.2220.883.19
Net Income From Continuing Operations29.5221.7124.0227.4626.5317.2220.883.19
Net Income29.5221.7124.0227.4626.5317.2220.883.19
EPS (Recurring)0.730.740.640.730.580.570.540.13
EPS (Basic, Before Extraordinaries)0.730.530.590.680.650.430.520.08
EPS (Diluted)0.720.530.590.670.650.420.510.08
EBITDA63.7363.9260.4267.3160.7245.9151.1143.81
Non-Operating Income (Expense)1.39-5.11-1.66-1.42-2.45-0.845.83-10.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.640.330.320.340.270.140.140.14
Price To Earnings Ratio13.8213.4924.5222.4634.1132.6844.8748.92
Price To Sales Ratio0.950.851.511.041.180.800.730.77
Gross Margin33.0433.6832.5635.3932.8028.4930.4431.92
Operating Margin12.9712.7512.5114.5513.168.8511.0710.42
Net Margin7.635.476.267.347.294.556.001.03
Shares Outstanding40.6040.5640.5640.5340.5340.5340.5340.50
Market Capitalization1,406.441,273.732,244.741,516.201,639.991,035.23865.16850.58

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments81.9977.04114.6181.2891.2593.2191.3481.5779.24
Short Term Receivables238.79227.98169.45163.48166.54146.85126.52159.02135.74
Inventories534.88444.43265.91277.57259.16216.31196.66198.32178.17
Other Current Assets79.8361.1651.0263.3949.2942.5337.3127.2522.31
Total Current Assets935.51810.61601.00585.72566.23498.91451.84466.16415.46
Net Property, Plant & Equipment420.75396.03240.90231.33203.17187.67170.98140.24130.11
Total Investments and Advances15.7611.7811.4921.3223.3212.8010.029.6314.26
Long-Term Note Receivable--------0.00
Intangible Assets90.1096.1199.59108.26117.09114.96123.6874.8379.33
Deferred Tax Assets17.0125.5519.378.715.859.8611.4316.7715.42
Other Assets22.1220.829.8316.0616.0417.1216.1619.0517.10
Total Assets1,501.241,360.90982.18971.40931.70841.33784.10726.67671.68
Short Term Debt Incl. Current Port. of LT Debt35.6025.3837.2628.3521.0515.9925.1912.5412.58
Accounts Payable127.31138.2085.5773.8595.6068.3666.0973.1959.50
Income Tax Payable22.138.402.938.667.216.113.826.073.61
Other Current Liabilities131.43121.5078.3965.1466.9773.6562.1462.4367.53
Total Current Liabilities316.47293.47204.15176.00190.83164.12157.24154.23143.22
Long Term Debt753.17736.17488.20481.62449.43410.71385.53313.63299.80
Provision for Risks Charges5.395.335.456.506.415.349.6111.077.55
Deferred Tax Liabilities25.0119.4714.2212.159.266.6511.688.989.73
Other Liabilities15.7320.7713.5212.6313.3115.9831.8422.7526.42
Total Liabilities1,115.761,075.22725.54688.89669.26602.80595.90510.66486.73
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity385.48285.68256.64282.51262.44238.53188.20216.01184.95
Total Shareholders Equity385.48285.68256.64282.51262.44238.53188.20216.01184.95
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity385.48285.68256.64282.51262.44238.53188.20216.01184.95
Total Liabilities & Stockholders Equity1,501.241,360.90982.18971.40931.70841.33784.10726.67671.68
Book Value Per Share9.507.056.346.976.485.894.655.344.58
Tangible Book Value Per Share7.284.683.884.303.593.051.603.492.62
Full-Time Employees2,6052,4751,9401,9201,8601,7251,7001,6001,500
Price to Book Ratio3.373.892.511.962.954.905.656.0110.01
Return on Assets6.974.120.253.435.556.694.447.8310.02
Return on Equity29.7217.800.9011.9719.6325.4916.6027.2938.61
Return on Invested Capital8.764.720.324.276.918.385.8510.3313.38
Quick Ratio1.271.251.641.751.611.721.621.741.66
Current Ratio2.962.762.943.332.973.042.873.022.90

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income102.7199.7248.262.4232.6149.1754.3833.5554.71
Depreciation52.2651.5145.6036.1834.0132.7031.8832.1227.52
Other Funds (Non Cash)6.145.5912.7027.93-9.34-4.79-5.91-0.790.99
Funds from Operations170.08164.05101.6954.4854.4476.2978.1773.0083.11
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-84.34-95.10-21.5633.11-41.13-44.64-29.87-13.66-35.94
Cash from Operating Activities85.7368.9580.1287.5913.3131.6548.3159.3547.17
Capital Expenditures-64.06-59.09-38.29-41.24-51.79-37.04-29.32-34.05-29.89
Net Assets From Acquisitions0.000.00-286.53-3.280.00-13.510.00-54.55-9.84
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments4.93-11.5735.00-4.00-23.0027.3512.00-31.0026.00
Purchase of Investments-38.10-47.60-14.00-65.52-40.00-64.10-74.00-80.00-34.00
Sale Or Maturity of Investments43.0336.0349.0061.5217.0091.4586.0049.0060.00
Other Uses2.75-0.790.000.000.000.00-1.26-0.80-0.40
Other Sources0.000.001.130.330.780.620.000.000.00
Cash from Investing Activities-56.39-71.45-288.69-48.19-74.02-22.58-18.58-120.39-14.13
Cash Dividends Paid-19.47-19.46-19.45-19.44-19.44-19.44-19.43-19.42-18.59
Change in Capital Stock0.000.000.000.000.000.000.000.001.13
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.000.000.001.13
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.001.13
Issuance or Reduction of Debt, Net-10.0112.18225.6112.7141.2140.622.4460.3513.35
Change in Long Term Debt-10.0112.18225.6112.7141.2140.622.4360.3513.35
Issuance of Long Term Debt359.43296.431,171.62276.00324.53297.00614.56243.00216.78
Reduction of Long Term Debt-369.44-284.25-946.01-263.30-283.31-256.38-612.12-182.65-203.42
Net Financing Active Other Cash Flow0.950.720.97-0.035.22-4.840.000.000.00
Other Financing Activities Uses-7.46-7.69-6.56-8.62-1.14-4.840.000.000.00
Cash from Financing Activities-28.53-6.56207.13-6.7726.9916.34-17.0040.94-4.11
Exchange Rate Effect1.962.44-1.14-3.300.75-1.371.14-1.12-0.52
Net Change in Cash2.78-6.62-2.5729.33-32.9724.0413.87-21.2328.41
Free Cash Flow21.679.8741.8346.36-38.48-5.3918.9925.3017.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow665.67-46.4225.25---180.81-
Deferred Taxes & Investment Tax Credit-7.23-4.88-12.04-2.84-0.81-2.188.12-0.10

Balance sheet, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Cash & Short Term Investments83.1281.9977.4574.5185.2777.04
Short Term Receivables221.71238.79221.55215.87217.90227.98
Inventories567.14534.88539.70517.35471.77444.43
Other Current Assets73.2079.8355.3754.4660.8561.16
Total Current Assets945.17935.51894.07862.18835.80810.61
Net Property, Plant & Equipment423.71420.75408.51394.80394.93396.03
Total Investments and Advances24.7415.7613.2613.0413.4011.78
Intangible Assets88.3390.1091.5792.8894.6796.11
Deferred Tax Assets10.2517.0115.2619.5023.5425.55
Other Assets22.5222.1222.4523.1523.1820.82
Total Assets1,514.721,501.241,445.121,405.551,385.521,360.90
Short Term Debt Incl. Current Port. of LT Debt34.9135.6032.2529.6027.4625.38
Accounts Payable136.45127.31129.64133.30130.60138.20
Income Tax Payable18.9822.1312.4810.6710.618.40
Other Current Liabilities105.44131.43107.50108.81101.46121.50
Total Current Liabilities295.79316.47281.87282.37270.14293.47
Long Term Debt754.21753.17755.19743.57757.63736.17
Provision for Risks Charges5.265.395.395.425.335.33
Deferred Tax Liabilities26.0925.0123.6122.0520.6119.47
Other Liabilities15.7115.7317.2319.7920.1420.77
Total Liabilities1,097.051,115.761,083.291,073.191,073.841,075.22
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity417.67385.48361.83332.36311.68285.68
Total Shareholders Equity417.67385.48361.83332.36311.68285.68
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity417.67385.48361.83332.36311.68285.68
Total Liabilities & Stockholders Equity1,514.721,501.241,445.121,405.551,385.521,360.90
Book Value Per Share10.299.508.928.207.697.05
Tangible Book Value Per Share8.117.286.665.915.354.68
Full-Time Employees-2,605---2,475
Price to Book Ratio3.373.526.754.865.743.89
Return on Assets7.086.976.906.845.774.12
Return on Equity28.1729.7230.3431.8023.7917.80
Return on Invested Capital2.521.912.152.552.481.69
Quick Ratio1.281.271.261.221.351.25
Current Ratio3.202.963.173.053.092.76

Cash flow, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Net Income29.5221.7124.0227.4626.5317.22
Depreciation13.5813.3512.4512.8912.8312.41
Other Funds (Non Cash)1.871.242.780.251.31-2.47
Funds from Operations48.8733.8542.9144.4442.8435.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-22.79-9.76-26.71-25.09-33.54-14.25
Cash from Operating Activities26.0824.0916.2119.359.3021.27
Capital Expenditures-18.78-18.87-15.32-11.10-13.81-13.14
Net Assets From Acquisitions0.000.000.000.000.005.35
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments13.001.95-3.50-6.52-3.501.00
Purchase of Investments-3.00-10.57-13.00-11.52-12.50-4.00
Sale Or Maturity of Investments16.0012.529.505.009.005.00
Other Uses-0.170.472.010.43-3.700.00
Other Sources0.000.000.000.000.00-0.24
Cash from Investing Activities-5.95-16.45-16.81-17.18-21.01-7.03
Cash Dividends Paid-4.87-4.87-4.87-4.86-4.86-4.86
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net1.74-3.633.94-12.0623.94-9.06
Change in Long Term Debt1.74-3.633.94-12.0623.94-9.06
Issuance of Long Term Debt149.0075.4373.0062.0086.0053.00
Reduction of Long Term Debt-147.26-79.06-69.06-74.06-62.06-62.06
Net Financing Active Other Cash Flow-2.516.88-1.37-2.05-2.746.16
Other Financing Activities Uses-2.51-1.53-1.37-2.05-2.74-1.37
Cash from Financing Activities-5.63-1.61-2.30-18.9816.34-7.77
Exchange Rate Effect-0.370.462.34-0.470.111.21
Net Change in Cash14.136.49-0.56-17.284.737.68
Free Cash Flow7.305.220.898.26-4.508.13
Price to Free Cash Flow665.67--54.98111.4946.44

Revenue breakdown

Medicated Feed Additives and Others2025: 646.35M
Mineral Nutrition2025: 253.24M
Nutritional Specialties2025: 179.29M
Performance Products2025: 80.18M
Total Pharmaceutical Preparations revenue2026: 1.52B
Vaccines2025: 137.15M
Asia Pacific2025: 97.42M
EMEA2025: 160.23M
Latin America and Canada2025: 298.65M
United States2025: 739.92M 2026: 1.52B
Animal Health2025: 962.80M
Mineral Nutrition2025: 253.24M
Performance Products2025: 80.18M
Total Pharmaceutical Preparations revenue2026: 1.52B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.87%1.0M20.9M219.58K
2026-10-154.94%1.0M20.9M228.99K
2026-09-304.88%1.0M20.9M241.62K
2026-09-155.48%1.1M20.9M246.86K
2026-08-315.79%1.2M20.9M267.77K
2026-08-145.92%1.2M20.8M287.61K
2026-07-315.72%1.2M20.9M356.29K
2026-07-155.84%1.2M20.9M362.80K
2026-06-305.83%1.2M20.9M356.30K
2026-06-155.90%1.2M20.9M367.09K
2026-05-295.28%1.1M20.9M350.97K
2026-05-155.65%1.2M20.9M333.60K
2026-04-305.95%1.2M20.4M300.30K
2026-04-156.12%1.2M20.4M292.76K
2026-03-315.71%1.2M20.5M277.56K
2026-03-135.86%1.2M20.5M262.54K
2026-02-275.31%1.1M20.5M266.18K
2026-02-135.23%1.1M20.5M279.54K
2026-01-305.15%1.1M20.5M275.82K
2026-01-155.26%1.1M20.3M283.99K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call17.5015.2019.400.005.1370.000.000.901-0.2520.010
call20.0012.7016.800.004.2800.000.000.882-0.2440.011
call22.5010.2014.300.003.6110.000.000.860-0.2320.012
call25.007.7011.900.003.0890.000.000.832-0.2180.014
call30.002.756.900.001.9950.000.000.747-0.1770.018
call35.000.052.804.961.3187.000.000.537-0.1760.022
call40.000.050.500.050.9201710.000.192-0.0770.015
call45.000.001.000.101.37915.000.000.142-0.0940.012
call50.000.000.400.001.6000.000.000.103-0.0830.010
put17.500.002.150.104.7942.000.00-0.099-0.2520.010
put20.000.002.150.004.0570.000.00-0.118-0.2420.011
put22.500.002.150.003.4190.000.00-0.141-0.2300.012
put25.000.002.150.352.8431.000.00-0.169-0.2150.014
put30.000.001.750.001.8040.000.00-0.254-0.1740.018
put35.000.453.601.651.60915.000.00-0.462-0.1740.022
put40.003.307.300.001.8100.000.00-0.809-0.0740.015
put45.008.1012.300.002.37314.000.00-0.858-0.0900.012
put50.0013.1017.300.002.8250.000.00-0.897-0.0860.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-03SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-19SCHEDULE 13G/ASEC
2026-09-18ARSAnnual report to security holders. 2026-06-30SEC
2026-09-18DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-18DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-03SEC
2026-09-174/A2026-08-06SEC
2026-09-174/A2026-08-06SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-08-268-KCurrent report2026-08-26SEC
2026-08-2610-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05317.70K11.02M3
2026-04003.50M9
2026-03003.38M9
2026-020012.19M12
2026-01002.35M10
2025-1200863.43K6
2025-11004.85M12

Institutional holders

Manager% owned
FMR LLC8.04%
BlackRock, Inc.7.94%
STATE STREET CORP2.56%
MILLENNIUM MANAGEMENT LLC2.31%
VANGUARD CAPITAL MANAGEMENT LLC2.28%
LORD, ABBETT & CO. LLC1.61%
GEODE CAPITAL MANAGEMENT, LLC1.50%
Advisors Asset Management, Inc.1.42%
DIMENSIONAL FUND ADVISORS LP1.33%
VANGUARD PORTFOLIO MANAGEMENT LLC1.25%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF3.13%
Fidelity Low-Priced Stock Fund1.95%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.63%
iShares Russell 2000 ETF1.35%
Strategic Advisers Fidelity U.S. Total Stock Fund1.00%
Lord Abbett Value Opportunities Fund0.85%
Oberweis Micro-Cap Fund0.74%
Fidelity Small Cap Growth Fund0.71%
VANGUARD EXTENDED MARKET INDEX FUND0.60%
Nuveen Quant Small Cap Equity Fund0.60%

OakChart. PAHC. Cached 15 minutes.